In our study, we found that the tumor inhibition rate in the combination therapy group was significantly higher than those in the other three groups and that no mice experienced significant increases in side effects while receiving recombinant human endostatin combined with radiotherapy as a treatment for colorectal cancer HCT-116 cell xenografts. This evidence concerns the gene COL18A1 and neoplasm.